xdhA Antibody

What is XDH protein and what role does it play in cellular metabolism?

XDH, also known as xanthine dehydrogenase/oxidase (XD, XO, XDHA, or XOR), belongs to the xanthine dehydrogenase family. It plays a crucial role in purine catabolism, catalyzing the final steps that convert hypoxanthine to xanthine and subsequently to uric acid. This 146 kDa protein (observed at 147-150 kDa in experimental conditions) is essential for proper purine degradation and metabolism . XDH has been identified as a moonlighting protein, meaning it can perform mechanistically distinct functions. The enzyme exists in two interconvertible forms: xanthine dehydrogenase, which uses NAD+ as an electron acceptor, and xanthine oxidase, which is formed through reversible sulfhydryl oxidation or irreversible proteolytic modification .

How do researchers differentiate between XDH's various nomenclature in the literature?

In scientific literature, researchers may encounter multiple designations for the same protein, which can cause confusion. XDH is officially referred to as xanthine dehydrogenase/oxidase with the gene symbol XDH, but it may also be referenced as:

• XDHA (historic nomenclature)

• XD (abbreviated form)

• XO (xanthine oxidase, its converted form)

• XOR (xanthine oxidoreductase, emphasizing its dual functionality)

When searching literature, researchers should include all these terms to ensure comprehensive results. The UniProt Primary Accession number P47989 and NCBI GeneID 7498 can also be used as unambiguous identifiers across databases .

What are the key structural characteristics of XDH that antibodies typically target?

XDH is a complex molybdenum-containing hydroxylase with a molecular weight of approximately 146 kDa. Most antibodies against XDH are designed to recognize specific epitopes within the protein structure. The protein contains domains associated with its enzymatic functions, including molybdenum cofactor binding sites, iron-sulfur centers, and NAD binding regions. Antibodies may target conserved regions for broad species reactivity or species-specific domains for enhanced specificity. For instance, antibody 55156-1-AP was generated against a peptide immunogen and successfully detects XDH at 147-150 kDa in Western blot applications . Understanding which domain an antibody targets is crucial for interpreting experimental results, especially when investigating the conversion between dehydrogenase and oxidase forms.

What are the optimal dilutions and conditions for Western Blot applications using anti-XDH antibodies?

Based on validated protocols, researchers should consider the following guidelines for Western blot applications:

Optimal results are typically achieved with liver tissue samples from mouse and rat models, which naturally express high levels of XDH . When working with human samples, researchers should note that expression levels may vary by tissue type. Always perform preliminary titration experiments with your specific samples to determine optimal antibody concentration. For protein extraction, phosphate buffers with protease inhibitors are recommended to preserve XDH integrity. Sample-dependent optimization may be necessary to achieve clear, specific bands at the expected molecular weight .

What protocols yield the best results for Immunohistochemistry with anti-XDH antibodies?

For immunohistochemistry applications with XDH antibodies, researchers should follow these methodological guidelines:

• Recommended dilution range: 1:50-1:500 (optimization required for specific tissues)

• Antigen retrieval: TE buffer at pH 9.0 is suggested as primary method

• Alternative approach: Citrate buffer at pH 6.0 may be used if TE buffer yields suboptimal results

• Positive control tissues: Human heart tissue has been validated for IHC applications

• Incubation conditions: Overnight incubation at 4°C typically provides optimal staining with minimal background

Detection systems based on horseradish peroxidase (HRP) conjugates are commonly used with DAB (3,3'-diaminobenzidine) as the chromogen. Counterstaining with hematoxylin provides excellent nuclear contrast as observed in validated samples . Researchers should be aware that XDH expression patterns vary across tissue types, with particularly strong expression in liver and intestinal epithelium.

What sample preparation methods optimize detection of XDH in different tissue types?

Effective sample preparation is critical for successful XDH detection across different experimental platforms:

For protein extraction (Western blot):

• Fresh tissue yields better results than frozen samples due to potential degradation

• Use RIPA buffer supplemented with protease inhibitors to prevent proteolytic cleavage

• Include reducing agents (e.g., DTT or β-mercaptoethanol) in sample buffers to maintain protein integrity

• Heat samples at 95°C for 5 minutes in Laemmli buffer for optimal denaturation

For tissue fixation (Immunohistochemistry):

• 10% neutral buffered formalin fixation for 24-48 hours provides consistent results

• Paraffin embedding followed by 5μm section thickness is standard

• Complete deparaffinization and rehydration are essential before antigen retrieval

• Blocking with 3-5% BSA or serum from the species of secondary antibody origin minimizes background staining

Liver tissues from mouse and rat models serve as excellent positive controls due to high endogenous XDH expression levels . For human samples, kidney tissue shows defined patterns of XDH expression as demonstrated through immunohistochemical analysis .

How can XDH antibodies be utilized to investigate the conversion between dehydrogenase and oxidase forms?

The interconversion between XDH and XO forms represents a significant regulatory mechanism with pathophysiological implications. Researchers can employ specific methodological approaches to investigate this phenomenon:

• Use non-reducing vs. reducing conditions in Western blot analysis to distinguish between oxidized (XO) and reduced (XDH) forms

• Employ activity-based assays in conjunction with antibody detection to correlate protein levels with enzymatic function

• Utilize antibodies that specifically recognize conformational epitopes present in only one form

• Perform immunoprecipitation followed by activity assays to assess the functional state of the captured protein

The conversion from XDH to XO can be induced experimentally through sulfhydryl oxidation or limited proteolysis . This conversion is particularly relevant in ischemia-reperfusion injury models where XO contributes to reactive oxygen species generation. When designing such experiments, researchers should consider time-course studies to capture the dynamic conversion process rather than single timepoint measurements.

What are the critical considerations when using XDH antibodies in disease model research?

When investigating disease models with XDH antibodies, researchers should account for several factors that impact experimental design and data interpretation:

• Disease-specific alterations in XDH expression levels and post-translational modifications

• Changes in XDH/XO ratio in pathological conditions, particularly in oxidative stress-related disorders

• Subcellular redistribution of XDH in response to cellular stress

• Potential cross-reactivity with related enzymes in inflammatory states

XDH defects are directly linked to xanthinuria type 1, characterized by excessive xanthine excretion and diminished uric acid levels . When studying this condition, antibody-based detection should be complemented with metabolic analyses to correlate protein expression with functional outcomes.

In cancer research models, XDH has been implicated in tumor metabolism and treatment response. Changes in expression patterns may serve as biomarkers for disease progression or therapeutic efficacy. Flow cytometry applications using XDH antibodies, such as those demonstrated with LOVO cells, can provide valuable insights into cellular distribution patterns in cancer cell populations .

How do researchers apply XDH antibodies in studies related to reactive oxygen species (ROS) generation?

XDH, particularly in its oxidase form (XO), is a significant source of reactive oxygen species in various pathological conditions. Researchers investigating ROS-related mechanisms can implement the following methodological approaches:

• Combine XDH antibody detection with dihydroethidium (DHE) staining to correlate protein expression with superoxide production

• Use dual immunofluorescence to co-localize XDH with oxidative damage markers like 8-OHdG or nitrotyrosine

• Perform sequential staining in tissue sections to detect XDH and downstream targets affected by ROS

• Implement in vitro models where XDH inhibition (pharmacological or genetic) is followed by comprehensive ROS assessment

Defects in XDH have been implicated in adult respiratory distress syndrome and may potentiate influenza infection through oxygen metabolite-dependent mechanisms . When studying these conditions, careful consideration should be given to sampling timing, as XDH-to-XO conversion can occur rapidly during sample processing, potentially confounding results.

What are the most common technical challenges when working with XDH antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with XDH antibodies:

When troubleshooting Western blot applications, the expected molecular weight of 147-150 kDa should serve as a reference point. Any significant deviations might indicate proteolytic processing or non-specific binding . For IHC applications, always include positive control tissues (human heart tissue has been validated) to confirm antibody performance in each experimental run .

How should researchers validate the specificity of XDH antibodies in their experimental systems?

Validating antibody specificity is crucial for generating reliable and reproducible data. For XDH antibodies, consider implementing these validation strategies:

• Positive controls: Use tissues known to express high levels of XDH (liver from mouse or rat) to confirm expected signal patterns

• Knockout/knockdown controls: When available, use XDH knockout models or siRNA-treated samples to confirm signal specificity

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to demonstrate signal elimination in true positive samples

• Multiple antibody approach: Use antibodies targeting different epitopes of XDH to confirm consistent detection patterns

• Orthogonal detection methods: Correlate antibody-based detection with mRNA levels or enzymatic activity measurements

For antibody 55156-1-AP, validation data is available for Western blot applications in mouse and rat liver tissues, and for IHC in human heart tissue . When working with different sample types, preliminary validation experiments should be conducted to establish optimal conditions and confirm specificity in the particular experimental context.

What cross-species reactivity considerations apply to XDH antibodies?

XDH is relatively conserved across mammalian species, but antibody cross-reactivity cannot be assumed without validation. When working with XDH antibodies across species:

• Review the antibody's tested reactivity data: For example, antibody 55156-1-AP has confirmed reactivity with human, mouse, and rat samples, with cited applications in chicken and bovine systems as well

• Align protein sequences: Compare the target epitope sequence across species to predict potential cross-reactivity

• Perform preliminary validation: Test the antibody on positive control samples from each species of interest

• Adjust protocols for species-specific optimization: Dilutions, incubation times, and detection methods may require adjustment

How are XDH antibodies being applied in antibody-based therapeutic development research?

While XDH antibodies are primarily used as research tools, emerging applications in therapeutic development include:

• Target validation studies: XDH antibodies help confirm the role of XDH/XO in disease pathogenesis, establishing it as a potential therapeutic target

• Pharmacodynamic biomarker development: Measuring XDH levels or activity in response to small molecule inhibitors

• Antibody-drug conjugate research: Exploring the potential of using XDH-targeting antibodies to deliver therapeutic payloads to tissues with high XDH expression

• Functional blocking antibody development: Investigating antibodies that could inhibit XDH/XO activity as potential therapeutics

The methodological approach to antibody design has advanced significantly with computational tools that integrate force field energy-based feedback during the diffusion process. This approach has demonstrated improved binding energy and structural stability in generated antibodies . Although not specifically developed for XDH antibodies, these methodological advances may be applicable to future therapeutic antibody development targeting XDH/XO.

What methodological approaches can researchers use to study XDH in the context of cellular immune responses?

Studying XDH in immune contexts requires specialized methodological approaches:

• Flow cytometry with XDH antibodies can detect expression levels in immune cell populations, similar to the approach demonstrated with LOVO cells

• Single-cell analysis combining XDH detection with immune cell markers can reveal cell type-specific patterns

• Immunofluorescence co-localization studies can examine XDH distribution in immune tissues

• In vitro stimulation models can assess how immune activation affects XDH expression and activity

Some researches suggest potential connections between XDH/XO activity and dendritic cell function, immune responses in transplantation, and inflammatory pathways. While XDH's role in purine metabolism is well-established, its function in immunomodulation represents an emerging area of investigation.

Similar to approaches used in vaccine development for targeting survivin in multiple myeloma, researchers might explore XDH as a potential immune target in certain conditions . Methodologically, this would involve evaluating immune responses directed against XDH in various disease states and examining potential correlations with clinical outcomes.

What are the latest computational approaches for predicting antibody-XDH interactions and optimizing experimental design?

Advanced computational methods are enhancing antibody research, including studies involving XDH:

• Force-guided sampling in diffusion models has demonstrated improved binding energy and structural stability for generated antibodies

• Energy landscape analysis can predict stable conformations of antibody-antigen complexes, potentially applicable to XDH interactions

• Structural conformity assessment throughout the diffusion process helps generate antibodies with better atomic coherence and fewer steric clashes

These computational approaches can help researchers:

• Predict optimal binding epitopes on XDH for antibody generation

• Design antibodies with enhanced specificity and affinity for XDH

• Optimize experimental conditions by modeling antibody-antigen interactions under various buffer conditions

While the DiffForce model described in the literature was not specifically applied to XDH antibodies, its methodology demonstrated superior performance in generating antibodies with improved binding scores and accuracy in recovering CDR sequences . These computational approaches represent valuable tools for researchers working with complex targets like XDH, potentially reducing experimental iterations and accelerating research progress.